Vabysmo vs Syfovre
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Vabysmo | US Syfovre | |
|---|---|---|
| Generic name | faricimab | pegcetacoplan |
| Drug class | VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) | Complement C3 Inhibitor |
| Treats | Wet macular degeneration, diabetic macular edema | Geographic atrophy (advanced dry AMD) |
| Category | Eye Health | Eye Health |
| Manufacturer | Genentech (Roche) | Apellis Pharmaceuticals |
| Year approved | 2022 | 2023 |
| FDA warning | No boxed warning | Moderate warnings |
| Est. TV ad spend | $85M | — |
| Common side effects | Eye inflammation, Floaters, Increased eye pressure, Blurred vision | Eye discomfort, Floaters, Bleeding in the eye, Increased eye pressure |
Frequently asked questions
Is Vabysmo or Syfovre better?
Neither is universally "better." Vabysmo (faricimab) and Syfovre (pegcetacoplan) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vabysmo and Syfovre?
Vabysmo is a VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) made by Genentech (Roche), while Syfovre is a Complement C3 Inhibitor made by Apellis Pharmaceuticals. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vabysmo has the larger estimated TV advertising budget of the two.